Blog

by Vineti | October 23, 2019
Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former CEO and Chairman of cancer genomics trailblazer Foundation Medicine. He is a leading voice on how the life sciences will continue to…

by Amy DuRoss | September 19, 2019
This fall, it will be 15 years since regenerative medicine faced a crisis of funding and support in the United States -- and the public stood up to pave a path forward. Now, at this milestone, it’s time to look ahead, and think about how we continue…

by Heidi Hagen | August 22, 2019
September marks the start of the autumn conference season in cell and gene therapy, and this fall, Vineti is looking forward to conversations that show how much the field of personalized therapeutics is growing. Our Chief Strategy Officer, Heidi…

by Vineti | August 8, 2019
Here are a few of the notable cell therapy and gene therapy updates from the past month.

by Amy DuRoss | July 30, 2019
While every day we seek to bring kaizen to cell and gene therapy,  we still have an important first step to accomplish as an industry (as we all know) -- standardization.  Without standardization, we can’t optimize or achieve truly “lean”…

Subscribe to our blog
Required
Required
Required
Required
Required
Required
Required